Details

Subject(s)

• Intellectual property [Browse]
• Patents [Browse]

Related name

• Possas, Cristina [Browse]

Summary note

This book presents expert opinions by frontier academicians, researchers, and attorneys on the recent challenges in the rapidly evolving life science industry.

Source of description

• Description based on publisher supplied metadata and other sources.
• Part of the metadata in this record was created by AI, based on the text of the resource.

Contents

• Cover
• Half Title
• Title Page
• Copyright Page
• Dedication
• Table of Contents
• Preface
• Acknowledgments
• About the Editors
• List of Contributors
• 1 The Need for Global Regulation of Gene Editing in the Wake of CRISPR-Cas9
• 1.1 Introduction
• 1.1.1 Breakthrough Technology
• 1.1.2 Bioethical and Human Rights Concerns About Gene Editing
• 1.1.3 The Importance of Continued Research
• 1.2 National Innovation Frameworks and IP Regimes
• 1.2.1 United States
• 1.2.2 European Union
• 1.2.2.1 The Oviedo Convention
• 1.2.2.2 EU Biotechnology Directive
• 1.2.2.3 Intellectual Property Barriers in the EU
• 1.2.2.4 Implementation By Select European Countries
• 1.2.3 China
• 1.3 Global Harmonization and Policy Recommendations
• Notes
• 2 IP Flexibilization for Accelerating the Achievement of the UN 2030 Agenda: Lessons From AIDS Programs in Brazil, India, Thailand, and Indonesia
• 2.1 Introduction
• 2.2 Conceptual Framework
• 2.3 IP Flexibilities and Licensing Agreements
• 2.4 Legal and Trade Disputes
• 2.5 Compulsory Licensing: Impact On Prices and Access
• 2.6 Lessons: Brazil, India, Thailand, and Indonesia
• 2.6.1 Brazil
• 2.6.2 India
• 2.6.3 Thailand
• 2.6.4 Indonesia
• 2.7 Lessons: Positive Impacts and Difficulties
• 2.8 The Medicine Patent Pool: Generic Competition and Voluntary Licensing
• 2.9 UN 2030 Unfinished Agenda for HIV/AIDS: Challenges
• 2.10 IP Into Epidemic Preparedness: Need for Integrated Policies
• 2.11 Final Considerations
• References
• 3 Cancer Drug Patent Disputes: Balancing Innovation, Access, and Ethics
• 3.1 Introduction
• 3.2 The Patent System and Cancer Drug Innovation
• 3.2.1 Patent System and Drug Development
• 3.2.2 How the Patent System Drives Innovation in Cancer Drugs
• 3.2.3 Access to Cancer Drugs and Patent Protection.
• 3.2.3.1 Patent-Induced Price Inflation and Its Impediments to the Accessibility of Cancer Drugs
• 3.2.3.2 Compulsory Licensing and Parallel Importation
• 3.2.3.3 Generic and Biosimilar Cancer Drugs
• 3.2.4 Ethical Issues in Cancer Drug Patent Disputes
• 3.2.4.1 Balancing Profit and Public Health
• 3.2.4.2 Ethical Challenges in Patenting Medicine
• 3.2.4.3 Patient Advocacy and Access to Essential Medication
• 3.2.5 Strategies to Balance Innovation and Access
• 3.2.5.1 Tiered Pricing and Differential Pricing Strategies
• 3.2.5.2 Public Private Partnerships and Nonprofit Drug Development
• 3.2.6 The World Trade Organization and TRIPS Agreement
• 3.3 Conclusion
• 4 Patent Disputes and Access to COVID-19 Vaccines: Structural Heterogeneity and Lessons for Disease X Preparedness
• 4.1 Introduction
• 4.2 Licensing in Technology Transfer Agreements: LAC and Africa
• 4.3 COVID-19: Global IP-Related Initiatives
• 4.3.1 COVAX Facility: Vaccine Support of ACT Accelerator
• 4.3.2 WHO Initiatives
• 4.3.2.1 MRNA Vaccines Hub: Afrigen and Other Countries
• 4.3.2.2 WHO COVID-19 Technology Access Pool (WHO C-TAP)
• 4.3.2.3 Genetic Sequences of Viral Samples Shared Openly Worldwide
• 4.3.2.4 Access to COVID-19 Tools Accelerator (ACT-A)
• 4.3.2.5 COVID-19 Vaccine Delivery Partnership
• 4.3.2.6 COVAX Manufacturing Task Force
• 4.3.2.7 WHO Emergency Use Listing
• 4.3.3 WTO Initiatives
• 4.3.4 WIPO Initiatives
• 4.3.4.1 WIPO COVID-19 Response Package
• 4.3.5 Government and Intergovernmental Initiatives
• 4.3.5.1 United States
• 4.3.5.2 European Commission
• 4.3.6 International Partnerships and Organizations
• 4.3.6.1 Coalition for Epidemic Preparedness Innovations (CEPI)
• 4.3.6.2 The World Bank
• 4.4 IP Governance for Disease X Preparedness: An Urgent Issue.
• 4.4.1 Disease X Pandemic: How Devastating Could It Be?
• 4.4.2 Vaccine Development: Challenges and Bottlenecks for a Disease X Pandemic
• 4.5 Conclusion and Future Trends
• 5 Analysis of Factors Associated With Patent Quality in Tissue Engineering
• 5.1 Introduction
• 5.2 Tissue Engineering and Patent Analysis
• 5.3 Methodology
• 5.4 Discussion and Analysis of Results
• 5.5 Conclusions
• 6 Vaccine Preparedness for Highly Pathogenic Avian Influenza: Innovation and Intellectual Property Issues
• 6.1 Introduction
• 6.2 Conceptual Framework and Overview
• 6.3 Materials and Methods
• 6.3.1 Launched HPAI Vaccines (Cortellis Drug Discovery Intelligence - CDDI)
• 6.3.2 Technological Analysis of Human Vaccines From Patent Applied Documents (Derwent Innovation)
• 6.3.3 Universal Influenza Vaccines
• 6.4 Results
• 6.4.1 Launched HPAI Vaccines
• 6.4.1.1 Flublok® Quadrivalent (Launched in 2017: USA)
• 6.4.1.2 AdimFlu-S® (QIS) - Quadrivalent Influenza Vaccine (Launched in 2017 in Taiwan)
• 6.4.1.3 VaxigripTetra®: Quadrivalent Inactivated Influenza Vaccine (Launched in 2017 in Europe)
• 6.4.1.4 Grippol® Quadrivalent: Quadrivalent Inactivated Subunit Adjuvanted Influenza Vaccine (Launched in 2018 in Russian Federation)
• 6.4.2 Patent Landscape - Human Vaccines
• 6.4.2.1 Institute of Experimental Medicine (Russian Federation)
• 6.4.2.2 Sanofi (From France)
• 6.4.2.3 Janssen (From US)
• 6.4.2.4 Seqirus UK Limited (From United Kingdom)
• 6.4.3 Universal Influenza Vaccines
• 6.5 Discussion
• 6.5.1 Vaccine Scale-Up: Bottlenecks
• 6.5.2 Applicants' Strategies
• 6.5.3 Technological Issues: MRNA and Universal Vaccines
• 6.5.4 Human and Veterinary Vaccines: One Health
• 6.6 Conclusion: Vaccine Preparedness
• References.
• 7 Intellectual Property Issues in Life Sciences: Contemporary Challenges and Considerations
• 7.1 Introduction
• 7.2 Laboratory-Based Molecular Biology Techniques
• 7.3 Publicly Available Datasets
• 7.4 The Big Data Revolution Comes With Issues
• 7.5 Conclusion
• 8 Navigating Regulatory Challenges and Intellectual Property Rights for Gene-Edited Crops: Implications for Plant Breeders, Farmers, and Consumers in a Changing Climate
• 8.1 Introduction
• 8.2 Navigating the Global Regulatory Landscape for Gene-Edited Products
• 8.3 Defining the Regulatory Status of Gene-Edited Crops and Governance Issues
• 8.4 Gene-Edited Crops and IPR Complexity
• 8.5 Conclusion
• Note
• 9 IP Rights and Food
• 9.1 Introduction
• 9.2 Gene Patenting
• 9.3 Climate-Ready Genes
• 9.4 Gene Editing
• 9.5 Industry Consolidation
• 9.6 Compulsory Licensing
• 9.7 Open-Source Biotechnology
• 9.8 Public Agricultural Research
• 10 Patents in Microbial β-Glucans and Pigments: Potential Commercial Products
• 10.1 Introduction
• 10.2 Microbial β-Glucans
• 10.3 Industrial Applications of Beta-Glucan
• 10.3.1 Food Industry
• 10.3.2 Pharmaceutical and Medical Industry
• 10.3.2.1 β-Glucan Application in Cancer Therapy
• 10.3.2.2 β-Glucans Used in Drug Formulation
• 10.3.3 β-Glucan in Immunotherapy
• 10.3.4 β-Glucan Application in Cosmetics
• 10.4 Microbial Pigments
• 10.5 Biopigment Applications
• 10.5.1 Food Industry
• 10.5.2 Biopigment Application in the Medical and Pharmaceutical Fields
• 10.5.3 Biopigment Application in Cosmetics
• 11 Menthol: The Story of a Plant-Derived Molecule Through the Patents
• 11.1 Introduction
• 11.2 A Scientific Overview of Menthol
• 11.3 The Country-Wise Market Analysis of Menthol-Based Products.
• 11.4 Analysis of the Patent Data for Menthol and Its Derivatives
• 11.4.1 First Menthol and Its Derivative-Related Patent
• 11.4.2 Patent Documents and Publication Date
• 11.4.3 Inventors and Applicants
• 11.4.4 Patent Jurisdictions
• 11.4.5 International Patent Classifications
• 11.5 Future Trends and Recommendations
• 11.6 Conclusions
• 12 Technology Transfer in the Field of Biotechnology: Concepts, Actors, Models, and Processes
• 12.1 Introduction
• 12.2 Elements, Models, and Technology Transfer Processes
• 12.3 Actors and Dynamics in Technology Transfer
• 12.4 Technology Transfer and Biotechnology
• 12.5 Methodological Approach
• 12.6 Conclusion
• Index.

Show 172 more Contents items

ISBN

• 9781040144671
• 1040144675
• 9781040144626
• 1040144624
• 9781003405665
• 1003405665

OCLC

1458757236

Statement on responsible collection description

Princeton University Library aims to describe library materials in a manner that is respectful to the individuals and communities who create, use, and are represented in the collections we manage. Read more...